Abstract:Acute myeloid leukemia (AML) is a group of heterogeneous diseases. Abnormalities in genes that encode transcription factors and tyrosine kinases represent two classes of the most frequently detected genetic events in human AMLs. Recently, a new category of gene mutations associated with epigenetic regulation have also been proposed. Recurrent somatic mutations of DNMT3A were identified in 23 of 112 (20.5%) cases using exome sequencing technique. The DNMT3A mutants showed reduced enzymatic activity or aberrant affinity to histone H3 in vitro. Gene expression profiles and DNA methylation patterns showed some differences between patients with and without DNMT3A mutations. Notably, we found that members of HOXB genes were extensively upregulated with mutations of DNMT3A, and hypomethylation of certain CpG islands in the HOXB locus. DNMT3A mutations enabled 32D cells to acquire growth and survival advantage with and without IL3. Leukemias with DNMT3A mutations constituted a group of poor prognosis with elderly disease onset. These data suggest a contribution of aberrant DNA methyltransferase activity to the pathogenesis of acute monocytic leukemia and provides a useful new biomarker for relevant cases. We performed the study to systemically investigate the frequencies and the prognostic relevance of previously known genetic events and newly established molecular markers in a large series of 1,185 adult AML patients. In particular, we intent to stratify the AML patients who lacked cytogenetic prognostic markers into appropriate prognostic groups. Multivariate analysis identified DNMT3A and MLL mutations as independent factors predicting inferior overall survival (OS) and event free survival (EFS), while bi-allelic CEBPA mutations or NPM1 mutations without DNMT3A mutations conferred a better OS and EFS in whole group and younger patients aged less than 60 years. Further studies will be focused on using different treatment strategies according to AML genotypes. Acute myeloid leukemia (AML) is a group of heterogeneous diseases. Abnormalities in genes that encode transcription factors and tyrosine kinases represent two classes of the most frequently detected genetic events in human AMLs. Recently, a new category of gene mutations associated with epigenetic regulation have also been proposed. Recurrent somatic mutations of DNMT3A were identified in 23 of 112 (20.5%) cases using exome sequencing technique. The DNMT3A mutants showed reduced enzymatic activity or aberrant affinity to histone H3 in vitro. Gene expression profiles and DNA methylation patterns showed some differences between patients with and without DNMT3A mutations. Notably, we found that members of HOXB genes were extensively upregulated with mutations of DNMT3A, and hypomethylation of certain CpG islands in the HOXB locus. DNMT3A mutations enabled 32D cells to acquire growth and survival advantage with and without IL3. Leukemias with DNMT3A mutations constituted a group of poor prognosis with elderly disease onset. These data suggest a contribution of aberrant DNA methyltransferase activity to the pathogenesis of acute monocytic leukemia and provides a useful new biomarker for relevant cases. We performed the study to systemically investigate the frequencies and the prognostic relevance of previously known genetic events and newly established molecular markers in a large series of 1,185 adult AML patients. In particular, we intent to stratify the AML patients who lacked cytogenetic prognostic markers into appropriate prognostic groups. Multivariate analysis identified DNMT3A and MLL mutations as independent factors predicting inferior overall survival (OS) and event free survival (EFS), while bi-allelic CEBPA mutations or NPM1 mutations without DNMT3A mutations conferred a better OS and EFS in whole group and younger patients aged less than 60 years. Further studies will be focused on using different treatment strategies according to AML genotypes.

Biologico-clinical significance of DNMT3A variants expression in acute myeloid leukemia.

Gene expression profiling of the DNMT3A R882 mutation in acute leukemia.

DNMT3A gene mutations in acute myeloid leukemia]

[The Expression of DNA Methyltransferase DNMT1, 3A and 3B in Acute Leukemia and Myelodysplastic Syndrome].

DNMT3A Gene Mutations in Acute Myeloid Leukemia——Review

Clinical Features and MicroRNA Expression Patterns Between AML Patients with DNMT3A R882 and Frameshift Mutations

Dnmt3a Haploisufficiency Cooperates with Oncogenic Kras to Promote an Early-Onset T-Cell Leukemia

DNMT3A mutations and clinical features in Chinese patients with acute myeloid leukemia

Epigenetic Landscape Analysis of Lncrnas in Acute Myeloid Leukemia with DNMT3A Mutations.

The impact of DNMT3A variant allele frequency and two different comutations on patients with de novo cytogenetically normal acute myeloid leukemia

Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML

[Analysis of DNMT3a gene mutations in acute myelogenous leukemia]

Role of DNA methyltransferase 3A in hematological malignancies

Genetic and epigenetic changes contributing to leukemogenesis and prognostic impact in acute myeloid leukemia

DNMT3A Mutation Analysis in Adult Patients with Acute Lymphoblastic Leukemia

Loss of Dnmt3b Accelerates MLL-AF9 Leukemia Progression

Exome Sequencing Identifies Somatic Mutations of DNA Methyltransferase Gene DNMT3A in Acute Monocytic Leukemia.

Significance of targeting DNMT3A mutations in AML

The Incidence of DNA Methyltransferase 3 Alpha(dnmt3a)gene Mutation in Patients with Acute Myeloid Leukemia(aml)and Its Clinical Significance

Clinical characteristics of acute myeloid leukemia with DNMT3A R882 mutation

DNMT3A-R882: a mutation with many paradoxes